Proactive Investors - Run By Investors For Investors

“It is important to keep adding products,” says Clinigen’s Chilton

Shaun Chilton, deputy chief executive of ambitious specialty pharma group Clinigen (LON:CLIN), says the company is making strides towards its goal of owning ten products by 2020.

The firm, which also released its interim results this morning, announced it has bulked up its medicine cabinet with the acquisition of a product called Totect, which is used in cancer care.

The product is used to treat toxic effects of anticancer treatment - Anthracycline - and is licensed in the US, where “interestingly, at the moment there is no treatment, for this particular indication,” Chilton says.

Totect is Clinigen’s sixth product since its inception in 2010, and Chilton says “we are maintaining that strike rate of a product a year.”

Meet Advanced Oncotherapy, VolitionRx, Scancell Holdings Plc, Faron Pharmaceuticals Oy and Highlands Natural Resources Plc at our event, London, 26 January 2017. Register here »
View full CLIN profile

Clinigen Group PLC Timeline

December 15 2016
November 11 2016
October 25 2016
October 18 2016

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.